ASH: Further data strengthens the case for Reblozyl

10 December 2023
bristol_myers_squibb_shutterstock_large

US pharma major Bristol Myers Squibb (NYSE: BMY) has presented updated results from the primary analysis of the Phase III COMMANDS trial at the 2023 American Society of Hematology (ASH) Annual Meeting.

The trial is comparing Reblozyl (luspatercept-aamt) versus epoetin alfa for the treatment of anemia in erythropoiesis stimulating agent (ESA)-naïve patients with lower-risk myelodysplastic syndromes (MDS) who may require red blood cell (RBC) transfusions.

"The analysis confirms that Reblozyl demonstrated clinical benefit across subgroups"Epoetin was originally manufactured and marketed by Amgen (Nasdaq: AMGN) under the brand name Epogen. Johnson & Johnson (NYSE: JNJ) subsidiary Janssen has also sold the drug under the name Procrit.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology